583 related articles for article (PubMed ID: 27863199)
41. Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
Maleki LA; Baradaran B; Majidi J; Mohammadian M; Shahneh FZ
Hum Antibodies; 2013; 22(1-2):9-13. PubMed ID: 24284304
[TBL] [Abstract][Full Text] [Related]
42. Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment.
Coelho R; Marcos-Silva L; Ricardo S; Ponte F; Costa A; Lopes JM; David L
Expert Rev Anticancer Ther; 2018 Feb; 18(2):177-186. PubMed ID: 29241375
[TBL] [Abstract][Full Text] [Related]
43. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer.
Johnston FM; Tan MC; Tan BR; Porembka MR; Brunt EM; Linehan DC; Simon PO; Plambeck-Suess S; Eberlein TJ; Hellstrom KE; Hellstrom I; Hawkins WG; Goedegebuure P
Clin Cancer Res; 2009 Nov; 15(21):6511-8. PubMed ID: 19843662
[TBL] [Abstract][Full Text] [Related]
44. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
[TBL] [Abstract][Full Text] [Related]
45. Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates.
Chu Q
Curr Oncol Rep; 2023 Apr; 25(4):309-323. PubMed ID: 36763234
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
[TBL] [Abstract][Full Text] [Related]
47. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model.
Mizukami T; Kamachi H; Fujii Y; Matsuzawa F; Einama T; Kawamata F; Kobayashi N; Hatanaka Y; Taketomi A
Oncotarget; 2018 Sep; 9(73):33844-33852. PubMed ID: 30333914
[TBL] [Abstract][Full Text] [Related]
48. [Mesothelin in ovarian cancer].
Fraszczak K; Barczyński B; Polak G; Kułak K; Kotarski J
Pol Merkur Lekarski; 2013 Sep; 35(207):166-70. PubMed ID: 24224456
[TBL] [Abstract][Full Text] [Related]
49. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.
Tang Z; Feng M; Gao W; Phung Y; Chen W; Chaudhary A; St Croix B; Qian M; Dimitrov DS; Ho M
Mol Cancer Ther; 2013 Apr; 12(4):416-26. PubMed ID: 23371858
[TBL] [Abstract][Full Text] [Related]
50. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
[TBL] [Abstract][Full Text] [Related]
51. Mesothelin expression in human lung cancer.
Ho M; Bera TK; Willingham MC; Onda M; Hassan R; FitzGerald D; Pastan I
Clin Cancer Res; 2007 Mar; 13(5):1571-5. PubMed ID: 17332303
[TBL] [Abstract][Full Text] [Related]
52. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.
Hassan R; Williams-Gould J; Steinberg SM; Liewehr DJ; Yokokawa J; Tsang KY; Surawski RJ; Scott T; Camphausen K
Clin Cancer Res; 2006 Aug; 12(16):4983-8. PubMed ID: 16914588
[TBL] [Abstract][Full Text] [Related]
53. Antibody-drug conjugates in gynecologic malignancies.
Lee EK; Liu JF
Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
[TBL] [Abstract][Full Text] [Related]
54. Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells.
Bodey B
Expert Opin Biol Ther; 2001 Jul; 1(4):603-17. PubMed ID: 11727497
[TBL] [Abstract][Full Text] [Related]
55. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.
He J; Zhang Z; Lv S; Liu X; Cui L; Jiang D; Zhang Q; Li L; Qin W; Jin H; Qian Q
Cell Immunol; 2018 Jul; 329():31-40. PubMed ID: 29859625
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro.
Batchu RB; Gruzdyn OV; Mahmud EM; Chukr F; Dachepalli R; Manmari SK; Mostafa G; Weaver DW; Gruber SA
Surgery; 2018 Mar; 163(3):627-632. PubMed ID: 29336814
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy targeting mesothelin in acute myeloid leukemia.
Wang Q; Gong R
J Leukoc Biol; 2022 Oct; 112(4):813-821. PubMed ID: 35946307
[TBL] [Abstract][Full Text] [Related]
58. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
Yokokawa J; Palena C; Arlen P; Hassan R; Ho M; Pastan I; Schlom J; Tsang KY
Clin Cancer Res; 2005 Sep; 11(17):6342-51. PubMed ID: 16144939
[TBL] [Abstract][Full Text] [Related]
59. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
60. The use of monoclonal antibody immunoconjugates in cancer therapy.
Pietersz GA; Krauer K; McKenzie IF
Adv Exp Med Biol; 1994; 353():169-79. PubMed ID: 7985535
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
